184 related articles for article (PubMed ID: 31155813)
1. A novel halobetasol propionate 0.01%/tazarotene 0.045% fixed combination treatment for psoriasis.
Radonjic A; Evans EL
Dermatol Ther; 2019 Jul; 32(4):e12979. PubMed ID: 31155813
[No Abstract] [Full Text] [Related]
2. Efficacy of a Once-Daily Fixed Combination Halobetasol (0.01%) and Tazarotene (0.045%) Lotion in the Treatment of Localized Moderate-to-Severe Plaque Psoriasis.
Blauvelt A; Green LJ; Lebwohl MG; Yamauchi PS; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):297-299. PubMed ID: 30909352
[TBL] [Abstract][Full Text] [Related]
3. Long-term safety results from a phase 3 open-label study of a fixed combination halobetasol propionate 0.01% and tazarotene 0.045% lotion in moderate-to-severe plaque psoriasis.
Lebwohl MG; Sugarman JL; Gold LS; Pariser DM; Lin T; Pillai R; Martin G; Harris S; Israel R
J Am Acad Dermatol; 2019 Jan; 80(1):282-285. PubMed ID: 30227193
[No Abstract] [Full Text] [Related]
4. Halobetasol and Tazarotene: Further Defining the Role of a Unique Fixed Combination Topical Lotion in Moderate-to-Severe Plaque Psoriasis.
Stein Gold L; Bagel J; Lebwohl M; Lin T; Martin G; Pillai R
J Drugs Dermatol; 2018 Dec; 17(12):1290-1296. PubMed ID: 30586261
[TBL] [Abstract][Full Text] [Related]
5. Treating Psoriasis With Halobetasol Propionate and Tazarotene Combination: A Review of Phase II and III Clinical Trials.
Ramachandran V; Bertus B; Bashyam AM; Feldman SR
Ann Pharmacother; 2020 Sep; 54(9):872-878. PubMed ID: 32126800
[No Abstract] [Full Text] [Related]
6. A Phase 2, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of a Halobetasol/Tazarotene Fixed Combination in the Treatment of Plaque Psoriasis.
Sugarman JL; Gold LS; Lebwohl MG; Pariser DM; Alexander BJ; Pillai R
J Drugs Dermatol; 2017 Mar; 16(3):197-204. PubMed ID: 28301614
[TBL] [Abstract][Full Text] [Related]
7. Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion for Moderate-to-Severe Psoriasis: Pooled Phase 3 Analysis of Lower Extremities.
Tyring S; Kircik LH; Yamauchi P; Jacobson A; Lin T
J Drugs Dermatol; 2020 Apr; 19(4):389-396. PubMed ID: 32272516
[TBL] [Abstract][Full Text] [Related]
8. Efficacy, Safety, and Tolerability of a Halobetasol 0.01% /Tazarotene 0.045% Fixed Combination in the Treatment of Severe Localized Plaque Psoriasis: Post Hoc Analysis of Two Phase III Randomized Controlled Trials.
Lebwohl MG; Sugarman JL; Stein Gold L; Lin T; Israel R
J Drugs Dermatol; 2019 Oct; 18(10):1012-1018. PubMed ID: 31584780
[TBL] [Abstract][Full Text] [Related]
9. Halobetasol 0.01%/Tazarotene 0.045% Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: Maintenance of Therapeutic Effect After Cessation of Therapy.
J Drugs Dermatol; 2019 Aug; 18(8):815-820. PubMed ID: 31424713
[TBL] [Abstract][Full Text] [Related]
10. DUOBRII™ (Halobetasol Propionate and Tazarotene) Lotion for Topical Use: A Newly Approved Combination Corticosteroid and Retinoid Topical Treatment of Plaque Psoriasis in Adults.
Gupta AK; Love RP; Abramovits W; Vincent KD
Skinmed; 2019; 17(3):181-183. PubMed ID: 31496472
[No Abstract] [Full Text] [Related]
11. Rapid Onset of Action in Patients With Moderate-to-Severe Plaque Psoriasis With Halobetasol 0.01%/Tazarotene 0.045% Fixed Combination.
Stein Gold L; Kircik LH; Pariser D; Sugarman JL; Lin T; Kang R; Pillai R
J Drugs Dermatol; 2018 Aug; 17(8):863-868. PubMed ID: 30124725
[TBL] [Abstract][Full Text] [Related]
12. Safety and Efficacy of a Fixed Combination Halobetasol and Tazarotene Lotion in the Treatment of Moderate-to-Severe Plaque Psoriasis: A Pooled Analysis of Two Phase 3 Studies.
Sugarman JL; Weiss J; Tanghetti EA; Bagel J; Yamauchi PS; Stein Gold L; Lin T; Martin G; Pillai R; Israel R
J Drugs Dermatol; 2018 Aug; 17(8):855-861. PubMed ID: 30124724
[TBL] [Abstract][Full Text] [Related]
13. Assessing the Synergistic Effect of a Fixed Combination Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion in Moderate-to-Severe Plaque Psoriasis.
Kircik LH; Papp KA; Stein Gold L; Harris S; Pharm TL; Pillai R
J Drugs Dermatol; 2019 Mar; 18(3):279-284.. PubMed ID: 30909333
[TBL] [Abstract][Full Text] [Related]
14. Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis.
Guenther L; Metelitsa A; Prajapati VH
Skin Therapy Lett; 2021 Nov; 26(6):1-3. PubMed ID: 34871475
[TBL] [Abstract][Full Text] [Related]
15. Comparison of clinical efficacy of topical tazarotene 0.1% cream with topical clobetasol propionate 0.05% cream in chronic plaque psoriasis: a double-blind, randomized, right-left comparison study.
Angelo JS; Kar BR; Thomas J
Indian J Dermatol Venereol Leprol; 2007; 73(1):65. PubMed ID: 17319037
[TBL] [Abstract][Full Text] [Related]
16. Combination of calcipotriene (Dovonex) ointment and tazarotene (Tazorac) gel versus clobetasol ointment in the treatment of plaque psoriasis: a pilot study.
Bowman PH; Maloney JE; Koo JY
J Am Acad Dermatol; 2002 Jun; 46(6):907-13. PubMed ID: 12063489
[TBL] [Abstract][Full Text] [Related]
17. Treatment of psoriatic nails with tazarotene cream 0.1% vs. clobetasol propionate 0.05% cream: a double-blind study.
Rigopoulos D; Gregoriou S; Katsambas A
Acta Derm Venereol; 2007; 87(2):167-8. PubMed ID: 17340027
[No Abstract] [Full Text] [Related]
18. Safety and efficacy of a fixed combination of halobetasol and tazarotene in the treatment of moderate-to-severe plaque psoriasis: Results of 2 phase 3 randomized controlled trials.
Gold LS; Lebwohl MG; Sugarman JL; Pariser DM; Lin T; Martin G; Pillai R; Israel R; Ramakrishna T
J Am Acad Dermatol; 2018 Aug; 79(2):287-293. PubMed ID: 29614243
[TBL] [Abstract][Full Text] [Related]
19. Long-Term Multiple Center Experience in Treating Plaque Psoriasis With Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion.
Abduelmula A; Gooderham MJ
J Cutan Med Surg; 2023; 27(3):291-292. PubMed ID: 36942447
[No Abstract] [Full Text] [Related]
20. Optimized formulation for topical application of a fixed combination halobetasol/tazarotene lotion using polymeric emulsion technology.
Tanghetti EA; Stein Gold L; Del Rosso JQ; Lin T; Angel A; Pillai R
J Dermatolog Treat; 2021 Jun; 32(4):391-398. PubMed ID: 31522563
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
